Introduction and Objective: CGM systems may support glucose control in patients in cardiac intensive care unit (CICU). We aimed to assess the accuracy, feasibility and tolerability of Dexcom One+ against standard blood glucose measurements.Methods: From September to December 2024, we included patients with known diabetes or hyperglycemia at admission >140 mg/dl hospitalized in the CICU due to acute coronary syndrome and/or heart failure. The accuracy was assessed by the mean absolute relative difference (MARD). Clinical performance was assessed using Consensus Error Grid (CEG) analysis. Feasibility outcome included number of early sensor detachment and sensor failure. Safety outcomes included skin reactions.Results: We obtained 567 paired samples from 27 patients (15 males), aged 72.3 ± 11.4 years. Among participants there were 22 patients with previously diagnosed T2DM. The mean HbA1c was 7.3 ± 1.4%. Overall, 419 paired samples were obtained during oxygen therapy, while 199 during vasopressor infusion. CGM use duration was 4.4 ± 3.2 days. The were 2 reference readings <70 mg/dl, 352 within 70-180 mg/dl range, and 213 >180 mg/dl. Overall MARD was 12.3%. Clinical accuracy is summarized in Table 1. We observed 1 mild hematoma at insertion site, 1 sensor failure and 2 early detachments.Conclusion: In patients in CICU Dexcom One+ demonstrated acceptable accuracy and could facilitate glucose monitoring.
J. Hohendorff: None. B. Zawislak: None. M. Bagienski: None. M.M. Adamczyk-Hohendorff: None. T. Klupa: Speaker’s Bureau; Lilly Diabetes, Novo Nordisk, AstraZeneca, Boehringer-Ingelheim, Sanofi. Research Support; Medtronic. Speaker’s Bureau; Medtronic, Abbott, Dexcom, Inc. M. Malecki: Speaker’s Bureau; Novo Nordisk, Lilly Diabetes, Sanofi, Boehringer-Ingelheim, AstraZeneca, Berlin-Chemie AG. Advisory Panel; Abbott, Dexcom, Inc. Speaker’s Bureau; Servier Laboratories. Other Relationship; Amryt Pharma.
Jagiellonian University Medical College Grant awarded to JH
Source link
Leave a Reply